Health Canada Approves Candela's Picoway for Melasma

Other new nods include lentigines, café au lait macules, and Nevus of Ota. 

Health Canada has granted Candela’s PicoWay laser system licensing for expanded indications, including the melasma, lentigines, café au lait macules (CALMs), and Nevus of Ota. 

The US Food and Drug Administration gave the device a similar same nod in October 2022. The new indications join earlier ones for wrinkles, benign pigmented lesions, tattoo removal, and acne scars.

The PicoWay laser platform has four true picosecond wavelengths (532, 730, 785 and 1064 nm) and offers treatment versatility with multiple available applicators and beam delivery technologies (full beam, microbeam and "Fusion" beam).

"Addressing melasma with the PicoWay laser gives patients an important treatment modality to manage this difficult and often psychologically upsetting condition. Patients now have a treatment that specifically targets their pigmentary changes and can be used alongside other treatments like topicals to better manage this complex skin disorder," says Douglas Wu, MD, PhD, a dermatologist of Cosmetic Laser Dermatology in San Diego and Rejuvenation Dermatology in Canada, in a news release.

"The new PicoWay laser clearances add to the already impressive capabilities of this platform. Candela is committed to investing in clinical research and expanding our products' range of cleared clinical indications. The PicoWay system's newest clearances allow our customers to continue benefiting from their partnership with Candela and offer their patients another clinically proven option for the treatment of melasma," says Geoff Crouse, CEO of Candela.